cyrilzakka/clinical-trials huggingface dataset:
Are Doctors Familiar With the Test Characteristics of Lung Cancer Screening?

This study evaluates whether doctors are familiar with the statistical background of lung cancer screening.

Background: Screening with low-dose CT scan can prevent three deaths due to lung cancer among 1000 high-risk individuals. However, false-positive results and radiation exposure are relevant disadvantages deserving accurate consideration. Candidates for screening can only make an autonomous decision if doctors inform them correctly about the pros and cons of the method. Therefore, this study aims to evaluate, whether doctors understand the test characteristics of lung cancer screening.

Methods: In a randomized trial, 556 doctors (members of the Austrian Respiratory Society) will be invited to answer questions regarding lung cancer screening based on online case vignettes. Half of the participants will be randomized to the group 'with data' and will receive the correct solutions in advance. The group 'without data' will have to rely on prior knowledge or estimate. Primary endpoint will be the between-groups difference in the estimated number of deaths preventable by screening. Secondary endpoints will be the between-groups differences in prevalence of lung cancer, prevalence of suspicious results, sensitivity, specificity, positive-predictive value, and false negative rate. Estimations will also be compared to actual values from the literature.

Eligibility Criteria:
Inclusion Criteria:

* Doctors, who were in training or had a completed specialization training in:
* Pneumonology
* Internal Medicine
* Surgery
* or Radiology

Exclusion Criteria:

* Doctors, with a specialized training in
* ENT
* Pediatrics
* Pathology and doctors who had no e-mail address were excluded.
Immune and Cognitive Benefits of Mango Intake in Young Adults

The main objectives of our proposed study are to determine the effects of mango consumption on immune and cognitive functions in free-living college going young adults aged 18-30 years

The main objectives of our proposed study are to determine the effects of mango consumption on immune and cognitive functions in free-living college going young adults aged 18-30. To accomplish these objectives, a randomized controlled, parallel design study is proposed with two groups consuming their habitual diet, but with one (Mango group) receiving 1.5 servings of mango/day and the other (Control group) abstaining from eating any mango for the duration of the study.

Eligibility Criteria:
Inclusion Criteria:

* Male and female college students aged 18-30 years

Exclusion Criteria:

* known intolerance or allergy to mangos
* regular intake of mangos and/or fruits of a similar nutritional content such as peach, nectarine, papaya, apricot and cantaloupe
* using cognition and/or immune-boosting supplements or vitamins
* recent exposure to antibiotics and corticoids
* uncontrolled chronic diseases and mental illnesses, clinical depression, and immunocompromised state
Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD

This study suggested that hydrogen has a potential as an effective and safe therapeutic agent on cGVHD.

The investigators will evaluate clinical response rate, time to treatment Failure (TTF), overall survival (OS), and toxicity in cGVHD patients.

Eligibility Criteria:
Inclusion Criteria:

* Written informed consent
* Male
* not pregnant female
* patients \<65 years old
* Diagnosis of cGVHD steroid refractory (no response after Prednisone ≥1mg/kg ) or steroid-dependent cGVHD (had an initial response followed by a cGVHD flare upon steroid taper)
* Patient intolerant to steroid therapy

Exclusion Criteria:

* Patients with stable disease, not well controlled by the current treatment
* Pregnancy
* HIV positive
* Severe liver or renal impairment: serum creatinine \>2.5 mg/dl; serum bilirubin\>2.5 mg/dl (without evidence of hepatic cGVHD)
* Uncontrolled malignancies including the persistence of the underlying malignancy before the Allogeneic Transplantation and the relapse of hematopoietic malignancy
* Any other investigational agents administered within last four weeks
* Cardiac insufficiency (\>grade II, New York Heart Association classification)
* Inability to comply with medical therapy or follow-up
The Efficacy of Tamsulosin and Tadalafil Compared to Placebo in the Treatment and Prevention of Urinary Disorders After Transperineal Prostate Biopsy

The purpose of this study is to evaluate the therapeutic efficacy of tamsulosin and tadalafil compared to placebo in the treatment and prevention of urinary disorders after transperineal prostate biopsy

After being informed about the clinical study and all the risks, all patients will be given a written informed consent. They will be randomised in three groups: A (tadalafil),B (tamsulosin) and C (placebo) and the drug or placebo will be administrated seven days before and seven days after transperineal prostate biopsy. Thirty minutes before the biopsy, all patients will receive a prophylactic antibiotic (ceftriaxone 2g intravenously) and an analgetic ( naklofen 75mg intramuscular injection). Before the biopsy patients will do an uroflowmetry to determine the Qmax and ultrasound(US) of the urinary tract to determine residual urine. After the biopsy is performed the patient fills out the international prostate symptom score (IPSS/QoL), visual analog scale (VAS) for pain, International Index of Erectile Function (IIEF-5) and 36-Item Short Form Survey (SF-36) questionnaires. Seven days after the biopsy the patient discontinues with the therapy and makes a visit for routine control of uroflowmetry, US of the urinary tract and he previously mentioned questionnaires are filled out. After 30 days of the biopsy the patient makes a visit for regular control of the pathohistological findings, uroflowmetry and ultrasound of the urinary tract, along with filling out the questionnaires again.

Eligibility Criteria:
Inclusion Criteria:

* Every patient that is a candidate for first time prostate biopsy

Exclusion Criteria:

* previous complaints of the lower urinary tract; benign prostatic hyperplasia(BPH), overactive bladder (OAB), etc.
* previous urinary retention and catheterization
* previous prostate biopsies
* patients who were treated surgically or medically for BPH
* systemic diseases including uncontrolled diabetes
* neurological diseases
* hemorrhagic diathesis
* patients on anticoagulants therapy
* patients with urinary infections
Comparitive Study of Two Misoprostol Regimen in Early Pregnancy Termination

The aim of this study is to compare two misoprostol regimen in pregnancy termination.

Studies on determining the optimal dosage for misoprostol in pregnancy termination are continuing and still there is no evidence for ideal misoprostol regimen for pregnancy termination. The aim of this study is to compare two misoprostol regimen in pregnancy termination.

Eligibility Criteria:
Inclusion Criteria:

* All women who were candidates for early pregnancy termination because of fetal death or other medical conditions
* Before 14th week of gestation calculated according LMP or first trimester sonography

Exclusion Criteria:

* Chorioamnionitis
* Hypersensitivity to prosstaglandins
* Past medical history of cardiovascular, kidney or liver or lung diseases
* Positive history for uterus pathologies
* suspicious to extra-uterus pregnancy
* sign and symptoms of uterus infection
* Molar pregnancy
Malaria Incidence in Infants in Bancoumana, Mali

This study, conducted by the Malaria Research and Training Center at the Faculty of Medicine in Bamako and the NIAID will measure the frequency of occurrence of malaria in infants in Bancoumana, Mali. Information from the study will help in planning trials of malaria vaccines.

Healthy children from 6 weeks to 6 months of age who live in the Bancoumana health area may be eligible for this study. Candidates are screened with a physical examination and blood tests.

Participating children are visited at home for a total of about 17 visits to see if they are well. They come to the clinic every month during the 7-month study for a clinical evaluation, including a blood sample obtained by finger prick to test for malaria. Some of the blood collected may be stored and used for research. Children who become sick with malaria are treated for the disease.

This is an observational study to determine the burden of malaria in rural Malian infants. Infants will be identified during a village-wide census and at Expanded Program for Immunization (EPI) visits. After obtaining community consent, eligible infants' parents will be invited to bring infants to the clinic for screening. Enrolled infants will receive a baseline evaluation and monthly visits during the rainy season at which times they will receive interim evaluations and heel, toe, or finger pricks for determinations of hemoglobin, thick and thin blood films, malaria antibody titers (at first and last visit for each transmission season), and hemoglobin typing at one visit. Study subjects will also receive a weekly home visit to determine if they are well or ill. If ill or febrile at any visit, or if they present to the clinic for an unscheduled visit, subjects will receive a history and physical examination, heel, toe, or finger pricks for determinations of hemoglobin, thick and thin blood films, filter paper blood collection and an RDT for malaria. Diagnosis and treatment of malaria will be performed according to Mali National Malaria Control Program (NMCP) guidelines. Diagnosis and treatment of other conditions will be performed as determined by the treating clinician.

Eligibility Criteria:
* INCLUSION CRITERIA:

  1. Infants at least six weeks to less than 7 months of age at enrollment
  2. Known residents of the Bancoumana health area
  3. Good general health as determined by clinical exam
  4. Available for the 6-7 months duration of the trial
  5. Willingness to participate as evidenced by signing of the informed consent or fingerprinting by the parent or guardian

EXCLUSION CRITERIA:

1. Social, behavioral, cognitive, or psychiatric condition that in the opinion of the investigator affects the ability of the volunteer or the parent/legal guardian to understand and cooperate with the study protocol
2. Participation in an investigational vaccine or drug trial within 30 days of starting this study, or while this study is ongoing
3. Infant born to mother with known or suspected HIV/AIDS as determined by the clinician
Effects of Oral Nutrition Supplements in Children With Disease Associated Underweight

The purpose of this study is to test whether the provision of ONS to malnourished children across Europe, in addition to standard counselling, will improve weight gain and other outcomes.

The hypothesis to be tested is:

• Supplementation with ONS in malnourished paediatric patients will lead to increased WFH gain, as well as less malnutrition related complications (e.g. infections).

Primary outcome • The change in BMI z-score over the intervention period of 3 months

Secondary outcomes

• The change in WFH-weight for height (z-scores) over the intervention period of 3 months


Eligibility Criteria:
Inclusion Criteria:

1. Children treated at the participating paediatric centres during the study period (inpatients or outpatients)
2. Age between 24 months to 12 years at inclusion
3. WFH at inclusion \<- 1,5 SD - \>-2,5 SD (based on WHO) OR Decrease in WFH z-score of ≥1 SD within the last 3 months, and underlying disease with high risk of undernutrition
4. Children who would be considered candidates for oral nutrition intervention (but do not need tube feeding)
5. Written informed consent of parents/caregivers

Exclusion Criteria:

1. Children in need of intensive care
2. Inability to consume ONS (e.g. major gastrointestinal dysfunction)
3. Children, for whom normal nutrition intervention would be inappropriate (e.g. food intolerance, allergy)
4. Use of parenteral feeding and/or enteral tube-feeding
5. Severe edema (\>0.5 cm pitting edema on the dorsum of the foot)
6. Participation in another intervention study involving investigational or marketed products concomitantly or within two weeks prior to entry into the trial.
7. Children having received enteral nutrition treatment for underweight in the previous month
8. Oncology patients during chemo-, radio-therapy
9. Expected hospital stay at inclusion longer than 7 days

   -
Tai Chi for Patients With Essential Hypertension

Several studies investigating Tai Chi for hypertension have been carried out. However, investigators found the results were in high heterogeneity and poor methodological quality. Thus, investigators intend to provide high quality of the effectiveness and safety of Tai Chi for essential hypertension.


Eligibility Criteria:
Inclusion Criteria:

1. participants aged between 45 to 80 years;
2. participants diagnosed with mild to moderate hypertension, and meet the diagnostic criteria of mild to moderate hypertension according to 2018 Chinese guidelines for the management of hypertension (140≤SBP≤169 and/or 90≤DBP≤109);
3. participants with or without antihypertensive medication;
4. participants with no regular exercise in the past 3 months;
5. participants willing to comply with the study protocol;
6. participants willing to sign informed consent form.

Exclusion Criteria:

1. participants diagnosed with secondary hypertension or refractory hypertension;
2. participants with severe medical visceral condition and chronic diseases, such as diabetes, epilepsy, severe depression or anxiety, psychosis;
3. participants with severe bone and joint diseases or motor dysfunction limit ability to participant exercise;
4. participants with severe cognitive decline (Mini-Mental State Examination score, ≤ 20)
5. participants with weak muscle, poor balance or limited vision that would impede full participation in the study;
6. patients participate in other clinical trials at the same time.
Study of Gammalinolenic Acid for Juvenile Rheumatoid Arthritis

OBJECTIVES:

I. Determine the efficacy and safety of gammalinolenic acid in the treatment of childhood arthritis.

PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, cross over study of 12 months duration. Patients are stratified by type of juvenile rheumatoid arthritis (systemic onset vs pauciarticular disease vs polyarticular disease).

Patients are randomized to receive either gammalinolenic acid (GLA) or placebo (safflower seed oil) orally. Parents are asked to maintain the child's usual diet over the course of study.

Patients are followed at 3, 6, 9, and 12 months during study and at 6 months thereafter.

Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

* Juvenile rheumatoid arthritis (systemic onset, pauciarticular disease, and polyarticular disease)
* Active synovitis

--Prior/Concurrent Therapy--

* No more than 2 concurrent nonsteroidal antiinflammatory drugs
* No more than 2 concurrent second line agents (e.g., D-penicillamine, oral or injectable gold, antimalarials, methotrexate, sulfasalazine)
* Must have started second line agent at least 3 months prior to study
* Must be on stable doses of all medications for at least 1 month prior to study
* Prior prednisone allowed if started at least 3 months prior to study
The Effect of Education Based on Roy Adaptation Model for Infertile Individuals on Adaptation and Coping With Stress

Psychosocial counseling applied together with infertility treatment programs makes infertile women more resistant to stress, increases the effectiveness of infertility treatments and encourages infertile patients to continue treatment by improving their mental health.

It appears that learning adaptation strategies in infertile couples is concurrent with health promotion. In addition to medical treatments, it is aimed to add training to be given in accordance with the Roy Adaptation model, to adapt to the process and infertility, and to control stress in infertile individuals in the management of the process.

The study was planned to examine the effect of education based on the roy adaptation model for infertile individuals on adaptation and coping with stress.


Eligibility Criteria:
Inclusion Criteria:

* 18-45age difference

Primary infertility

Exclusion Criteria:

- Secondery infertility
Home Air Quality Impact for Adults with Asthma

The purposes of this study are to determine the practicality of using home indoor air quality monitoring and a smartphone app to identify home air quality changes and how these changes affect adults with asthma.

The aims of this feasibility study are: 1) determine the feasibility and usability of: (a) ecological momentary assessment (EMA) to assess self-report residential environmental exposures and asthma symptoms, (b) home monitoring of objective environmental exposures (total volatile organic compounds \[VOCs\], particulates \[PM2.5\]), and lung function (home spirometry); 2a) assess the frequency and degree of residential environmental exposures (e.g., disinfectants/cleaners, second-hand smoke) via (a) self-reported data, and (b) home monitoring objective measures, 2b) assess the level of asthma control as indicated by self-reported asthma symptoms and lung function; and 3) explore associations of self-reported and objective measures of residential environmental exposures with self-reported and objective measures of asthma control. Participants will receive an indoor air quality monitor and a home spirometer to measure VOCs, PM2.5, and forced expiratory volume percent predicted, respectively. EMA will be collected using a personal smartphone and EMA software platform. Participants' will be sent scheduled and random EMA notifications to assess asthma symptoms, environmental exposures, lung function, and mitigation strategies. After the 14-day data collection period, participants will respond to survey items related acceptability, appropriateness, and feasibility.

Eligibility Criteria:
Inclusion Criteria:

* Adults who previously participated in the online Global Covid-19 and Asthma Study, indicated willingness to be contacted for future research, and reported high use of disinfectant/cleaning products since COVID-19 (≥5 per week).
* Current Asthma Control Test (ACT) ≤19
* Own a smartphone
* Have a Wi-Fi/wireless internet connection in their home.

Exclusion Criteria:

* Non-US residents
* Non-English speaking
Hematopoietic Stem Cells Transplantation in Children With Combined Immunodeficiency (CID)

The purpose of this study is to evaluate selective depletion of naïve CD45RA+ T cells from allogenic peripheral blood stem cell graft in children transplanted for combined immune deficiency. The aims of this procedure are to prevent graft versus host disease (GVHD) while preserving anti-infectious response from donor memory T lymphocytes.

Combined immunodeficiencies (CIDs) are an heterogeneous group of primitive immunodeficiency (PID), which affect T cells development, function or both. These inherited conditions can only be cured by allogeneic hematopoietic stem cell transplantation (HSCT). These procedures have a high risk of morbidity and mortality such a graft versus host disease (GVHD), rejection of the graft and serious infections, especially in this population of children with PID. GVHD is more frequent and severe if the donor is not an identical sibling and/or presents an HLA-mismatch. GVHD requires high immunosuppression as prevention and treatment, and therefore impedes immunity against infections.

In vitro and animal models suggest that GVHD is mediated by naïve T cells. The aim of this study is to decrease the rate and severity of GVHD after selective depletion of naïve CD45RA+ T cells from allogeneic hematopoietic stem cell grafts in patients with CIDs with high risk of severe GVHD, and to preserve immunity against pathogens in a population with high vulnerability to infections.

The project aims is, first, to show improvement of rejection-free and GVH-free survival 12 months post-transplant, and secondly, to show the decrease of viral infection, and assess immune reconstitution kinetic and quality and specific antiviral responses, after a engraftment with naïve cell depleted allograft.

Eligibility Criteria:
Inclusion Criteria:

* Patient from 12 months to 18 years
* Combined immunodeficiencies with known molecular diagnosis or if unknown, corresponding of p-CID study's definition
* Hematopoietic stem cell Transplantation planned with one of the following donors :
* sibling with 1 or 2 HLA antigens mismatch
* parent 10/10 or 9/10 identical
* unrelated donor: 10/10 or 9/10 identical
* Consent form signed by the child's legal guardian
* Patient using effectiveness contraception during this trial
* Affiliated or beneficiary of a health insurance regimen

Exclusion Criteria:

* Wiskott-Aldrich syndrome
* Ongoing pregnancy
* Positive HIV PCR
* Contraindication for hematopoetic stem cell transplantation
* Geno-identical donor in the siblings
* hematopoetic stem cell transplantation antecedent
Indonesia Frailty, Aging, and Longitudinal Study

Frailty is a dynamic process from fit (robust) and pre-frail elderly. There is no previous study that determine the risk factors from fit to pre-frailty and pre-frailty to frailty in Indonesian elderly.

This study was aimed to define the risk factors and clinical outcomes of frailty transitional status in Indonesian elderly.

Frailty is an age-associated, biological syndrome characterized by decreased biological reserves, due to dysregulation of several physiological systems, which puts an individual at risk when facing minor stressors, and is associated with poor outcomes (ie, disability, death, and hospitalization).

Frailty identifies a high-risk subgroup and offers characteristics of great clinical importance: a higher reversibility at early stages than disability, and a higher predictive value than chronic disease for adverse outcomes at older ages. It is also the most common condition leading to death in community-dwelling older people.

However, there is current consensus that physical frailty is potentially reversible. It is hence useful to objectively detect frailty among frail elderly persons, as frailty indices serve a useful purpose for risk stratification, predicting need for institutional care and planning of services needed.

To date, there is no study or information about frailty status in Indonesia elderly. This study was aimed to define the risk factors and clinical outcomes of frailty transitional status in Indonesian elderly.

Eligibility Criteria:
Inclusion Criteria:

1. Elderly aged \>= 60 years old
2. Fit (robust) or pre-frailty;
3. Capable to understand and carry-out the instruction.

Exclusion Criteria:

1. Unwilling to join the study;
2. Abbreviated Mental Test (AMT) score \< 8;
3. Geriatric Depression Scale (GDS) score \>= 10;
4. Body mass index (BMI) \<18,5 Kg/m2;
5. Malnutrition (according to Mini Nutritional Assessment/MNA);
6. Liver cirrhosis, severe liver dysfunction, or serum ALT levels \>3 times upper normal limit;
7. Acute illness during inclusion period, eg. pneumonia, pain due to acute arthritis (visual analog scale \>6/10), stroke attack, crisis hypertension;
8. Severe cardiac dysfunction: acute decompensated heart failure and/or chronic heart failure functional class III or IV (New York Heart Association classification);
9. Severe pulmonary dysfunction: acute exacerbation of chronic obstructive lung disease stage III or IV (GOLD classification), and/or PaO2 levels \< 60 mmHg.